Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease

Johannes Schwarz, A. Antonini, E. Kraft, K. Tatsch, T. Vogl, C. M. Kirsch, K. L. Leenders, W. H. Oertel

Research output: Contribution to journalArticle

Abstract

We report the results of in vivo striatal dopamine D2-receptor binding assessed by PET using 11C-raclopride (only one patient) and by single-photon emission computed tomography (SPECT) using 123I-iodobenza-mide (123I-IBZM) and the findings of T2-weighted MRIs in two de novo Wilson's disease patients before and 4 months after initiation of D-penicillamine treatment. Before treatment, specific 11C-raclopride binding (only patient 1) was markedly reduced, with a putamen to cerebellum ratio of 1.99 (controls: 3.99 ± 0.55, n = 15) and a caudate to cereb0ellum ratio of 2.52 (controls: 3.65 ± 0.59, n = 15). Specific 123I-IBZM binding was reduced in both patients, with a basal ganglia to frontal cortex ratio of 1.25 (patient 1) and of 1.41 (patient 2) (controls: 1.57 ± 0.04, n = 5). After 4 months of therapy, 11C-raclopride-PET improved to a putamen to cerebellum ratio of 2.52 and a caudate to cerebellum ratio of 3.06(patient 1). 123I-IBZM-SPECT revealed an increase of basal ganglia to frontal cortex ratios of 1.34 (patient 1) and 1.55 (patient 2). On heavily T2-weighted MRI sequences, hyperintense signal changes before therapy within the putamen (both patients), brainstem (only patient 1), and caudate (only patient 2) greatly diminished after treatment. Reduced striatal dopamine D2-receptor binding in these Wilson's disease patients improved under therapy, suggesting, in part, a reversible defect of striatal neurons.

Original languageEnglish
Pages (from-to)1079-1082
Number of pages4
JournalNeurology
Volume44
Issue number6
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Treatment with d–penicillamine improves dopamine D<sub>2</sub>–receptor binding and T<sub>2</sub>–signal intensity in de novo wilson's disease'. Together they form a unique fingerprint.

  • Cite this

    Schwarz, J., Antonini, A., Kraft, E., Tatsch, K., Vogl, T., Kirsch, C. M., Leenders, K. L., & Oertel, W. H. (1994). Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease. Neurology, 44(6), 1079-1082.